Federal Circuit Strikes Down Merck’s MS Drug Patents: Hopewell Wins Obviousness Challenge

In a significant defeat for Merck KGaA, the Delaware District Court entered final judgment on January 29, 2026, in favor of generic pharmaceutical challenger Hopewell Pharma Ventures, Inc., invalidating two key patents protecting a cladribine regimen for treating progressive forms of multiple sclerosis (MS). The ruling, driven by a precedential Federal Circuit decision, found claims across U.S. Patent Nos. 7,713,947 and 8,377,903 invalid as obvious — clearing the path for Hopewell’s ANDA product to receive immediate FDA approval.

For patent attorneys and IP professionals navigating pharmaceutical patent litigation, this case offers a compelling study in how obviousness challenges, ANDA litigation dynamics, and appellate strategy intersect. For R&D teams and in-house counsel in the life sciences sector, the outcome underscores the continuing vulnerability of pharmaceutical method and formulation patents to validity attacks — even within established, commercially significant therapeutic categories like multiple sclerosis treatment.

Case No. 1:22-cv-01365 represents a critical data point in the evolving landscape of Hatch-Waxman litigation and pharmaceutical patent infringement defense.

Case Overview

The Parties

The Patents at Issue

Three patents were initially identified in this litigation, all relating to a **cladribine dosing regimen for treating progressive forms of multiple sclerosis**, a neurodegenerative condition affecting millions globally and representing a multi-billion-dollar therapeutic market. Design patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect ornamental appearance rather than functional technology.

• • US 7,713,947 — Cladribine dosing regimen for MS (Claims 36, 38, 39, 41–46 at issue)
• • US 8,377,903 — Cladribine dosing regimen for MS (Claims 17, 19, 20, 22–27 at issue)
• • US 10,849,919 — Also identified in the patent portfolio

Merck filed this infringement action on **October 17, 2022**, in the **Delaware District Court** — a jurisdiction renowned as the premier forum for pharmaceutical patent disputes due to its experienced judiciary and well-developed Hatch-Waxman jurisprudence. The filing automatically triggered a **30-month stay of FDA approval** of Hopewell’s ANDA product pursuant to 21 U.S.C. § 355(j)(5)(B)(iii).

The case proceeded at the district court level as a first-instance trial proceeding. Critically, the dispositive resolution came not from the district court’s own merits determination but from the **Federal Circuit’s ruling in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Nos. 2025-1210 and 2025-1211, 159 F.4th 10 (Fed. Cir. 2025)** — indicating that the validity challenge was adjudicated on appeal before the district court proceedings fully concluded, a procedural posture that signals early appellate engagement through interlocutory mechanisms or accelerated review.

The Federal Circuit’s mandate was entered on **January 29, 2026**, the same day the Delaware District Court entered final judgment — reflecting immediate implementation of appellate direction. Total case duration spanned from October 2022 to January 2026, approximately **39 months**.

The Verdict & Legal Analysis

Outcome

The Delaware District Court entered judgment **entirely in favor of Hopewell Pharma Ventures, Inc.** Specifically:

1. **Claims 36, 38, 39, and 41–46** of U.S. Patent No. 7,713,947 were found **invalid as obvious**
2. **Claims 17, 19, 20, and 22–27** of U.S. Patent No. 8,377,903 were found **invalid as obvious**
3. All infringement claims by Merck were dismissed; Merck takes **nothing** on those claims
4. The **30-month FDA stay was lifted**, permitting immediate final approval of Hopewell’s ANDA No. 215547
5. **Each party bears its own costs**; the case was found **not exceptional** under 35 U.S.C. § 285

No damages were awarded. No injunctive relief was granted to Merck.

Verdict Cause Analysis: Obviousness Under 35 U.S.C. § 103

The controlling legal basis for invalidation was **obviousness** — the doctrine under 35 U.S.C. § 103 requiring that a patent claim be non-obvious to a person having ordinary skill in the art (PHOSITA) at the time of the invention, considering prior art references in combination.

The Federal Circuit’s published decision at **159 F.4th 10** provides the authoritative reasoning. Pharmaceutical method-of-treatment claims — even those covering specific dosing regimens — remain vulnerable to obviousness challenges when prior art discloses the active compound’s use in the same therapeutic indication and when dosing parameters fall within ranges a skilled formulator would have explored with a reasonable expectation of success.

This pattern aligns with a broader Federal Circuit trend of applying rigorous obviousness scrutiny to pharmaceutical dosing regimen patents, particularly where the underlying compound’s therapeutic utility was previously known.

Legal Significance

The Federal Circuit’s published opinion (159 F.4th 10) carries **precedential weight** — a critical distinction from non-precedential rulings. This means the Federal Circuit’s obviousness analysis in this cladribine case may be directly cited in future pharmaceutical patent litigation challenging similar dosing regimen claims.

The court’s finding that the case was **not exceptional under 35 U.S.C. § 285** is also strategically notable. Despite a full invalidity ruling against Merck, the court declined to find the litigation objectively baseless or brought in bad faith — a conclusion that limits Hopewell’s ability to recover attorney fees and signals judicial deference to the legitimacy of good-faith patent enforcement, even when ultimately unsuccessful.